Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.7.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Consolidated Statements Of Operations    
Revenues, net $ 701,772 $ 924,732
Operating expenses:    
Cost of implants and other costs 175,430 151,970
Selling, general and administrative 2,545,311 2,125,882
Termination of licensing agreement 132,804 3,639,694
Depreciation and amortization 30,248 125,070
Total operating expenses 2,883,793 6,042,616
Loss from operations (2,182,021) (5,117,884)
Other income (expenses):    
Net gain on settlement agreement 731,973
Interest expense, net (1,048,013) (377,087)
(Loss) gain on change in fair value of derivative liability (2,673,948) 97,008
Total other income (expenses) (3,721,961) 451,894
Loss before income taxes (5,903,982) (4,665,990)
Income taxes
Net loss $ (5,903,982) $ (4,665,990)
Net loss per common share, basic and diluted $ (0.03) $ (0.03)
Weighted average number of common shares outstanding, basic and diluted 170,245,976 155,487,569